Evaluation of a Multidisciplinary Immunotherapy Toxicity Monitoring Program for Patients Receiving Ipilimumab for Metastatic Melanoma Ductal carcinoma in situ (DCIS), a nonobligate precursor of breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results